Compare Stocks: ARQT, ELAN, CORT, and AXSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$25.29 -4.3%	$26.05	$13.69 ▼ $31.77	$3.16B	1.49	1.44 million shs	2.45 million shs
AXSM Axsome Therapeutics	$212.74 +1.2%	$236.95	$102.67 ▼ $260.19	$10.95B	0.65	678,187 shs	1.02 million shs
CORT Corcept Therapeutics	$110.77 +2.6%	$89.31	$28.66 ▼ $122.21	$11.97B	0.45	1.40 million shs	769,035 shs
ELAN Elanco Animal Health	$22.06 -8.9%	$24.70	$16.15 ▼ $27.98	$11.05B	1.67	6.02 million shs	22.07 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	-5.85%	-12.13%	+19.46%	+64.65%
AXSM Axsome Therapeutics	0.00%	-2.41%	-14.55%	-2.13%	+106.02%
CORT Corcept Therapeutics	0.00%	-3.25%	+18.79%	+111.88%	+57.08%
ELAN Elanco Animal Health	0.00%	-16.52%	-10.46%	-6.28%	+57.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$25.29 -4.3%	$26.05	$13.69 ▼ $31.77	$3.16B	1.49	1.44 million shs	2.45 million shs
AXSM Axsome Therapeutics	$212.74 +1.2%	$236.95	$102.67 ▼ $260.19	$10.95B	0.65	678,187 shs	1.02 million shs
CORT Corcept Therapeutics	$110.77 +2.6%	$89.31	$28.66 ▼ $122.21	$11.97B	0.45	1.40 million shs	769,035 shs
ELAN Elanco Animal Health	$22.06 -8.9%	$24.70	$16.15 ▼ $27.98	$11.05B	1.67	6.02 million shs	22.07 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	-5.85%	-12.13%	+19.46%	+64.65%
AXSM Axsome Therapeutics	0.00%	-2.41%	-14.55%	-2.13%	+106.02%
CORT Corcept Therapeutics	0.00%	-3.25%	+18.79%	+111.88%	+57.08%
ELAN Elanco Animal Health	0.00%	-16.52%	-10.46%	-6.28%	+57.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	40.65% Upside
AXSM Axsome Therapeutics	2.91	Moderate Buy	$265.55	24.82% Upside
CORT Corcept Therapeutics	2.63	Moderate Buy	$119.17	7.58% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	31.88% Upside

Current Analyst Ratings Breakdown

Latest ARQT, ELAN, CORT, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/6/2026	ARQT Arcutis Biotherapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$34.00 ➝ $38.00
8/6/2026	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $38.00
8/6/2026	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $40.00
8/6/2026	ELAN Elanco Animal Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $33.00
8/6/2026	ELAN Elanco Animal Health	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$29.00 ➝ $30.00
7/31/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$310.00 ➝ $306.00
7/30/2026	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $165.00
7/30/2026	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$88.00 ➝ $165.00
7/29/2026	CORT Corcept Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $150.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$463.98M	6.82	N/A	N/A	$1.76 per share	14.37
AXSM Axsome Therapeutics	$708.24M	15.46	N/A	N/A	$1.75 per share	121.57
CORT Corcept Therapeutics	$761.41M	15.73	$0.90 per share	122.70	$6.53 per share	16.96
ELAN Elanco Animal Health	$5.02B	2.20	$2.31 per share	9.53	$13.19 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	120.43	23.42	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	52.40	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	263.74	47.14	N/A	6.52%	8.26%	6.45%	N/A
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	17.65	1.33	-3.96%	8.13%	3.99%	N/A

Latest ARQT, ELAN, CORT, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	N/A	N/A	N/A	$221.11 million	N/A
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.46
AXSM Axsome Therapeutics	2.27	1.39	1.32
CORT Corcept Therapeutics	N/A	2.86	2.77
ELAN Elanco Animal Health	0.58	2.05	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
ELAN Elanco Animal Health	97.48%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
AXSM Axsome Therapeutics	20.60%
CORT Corcept Therapeutics	20.70%
ELAN Elanco Animal Health	1.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	125.08 million	113.33 million	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
CORT Corcept Therapeutics	300	108.10 million	85.72 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable

ARQT, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

Elanco Animal Health (NYSE:ELAN) Price Target Raised to $33.00

August 9 at 4:15 AM | americanbankingnews.com

Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00

August 9 at 3:38 AM | americanbankingnews.com

Elanco Animal Health (NYSE:ELAN) Sees Large Volume Increase After Analyst Upgrade

August 9 at 2:40 AM | americanbankingnews.com

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World ...

August 8 at 4:06 AM | aol.comA

Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of "Moderate Buy" by Analysts

August 8 at 3:01 AM | americanbankingnews.com

Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 8 at 2:28 AM | marketbeat.com

Elanco Animal Health Q2 Earnings Call Highlights

August 8 at 2:02 AM | marketbeat.com

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

August 7 at 2:20 PM | prnewswire.com

Elanco Animal Health (NYSE:ELAN) Sees Unusually-High Trading Volume on Analyst Upgrade

August 7 at 1:39 PM | marketbeat.com

Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

August 7 at 3:12 AM | marketbeat.com

Cetera Investment Advisers Buys 65,526 Shares of Elanco Animal Health Incorporated $ELAN

August 7 at 3:03 AM | marketbeat.com

Elanco Animal Health (NYSE:ELAN) Hits New 12-Month High on Strong Earnings

August 7 at 1:41 AM | americanbankingnews.com

Elanco CEO on Boosted Forecast, Surge in Tick Bites

August 6 at 6:00 PM | youtube.comY

UBS Group Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $33.00

August 6 at 3:23 PM | marketbeat.com

ADUS vs. ELAN: Which Stock Is the Better Value Option?

August 6 at 12:41 PM | zacks.com

Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, KeyCorp Analyst Says

August 6 at 10:35 AM | marketbeat.com

Elanco Lifts Outlook as 2Q Profit, Revenue Rise

August 5, 2026 | marketwatch.com

Elanco Animal Health (NYSE:ELAN) Announces Earnings Results

August 5, 2026 | marketbeat.com

Elanco Animal Health Incorporated (ELAN) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Elanco posts Q2 beat as Zenrelia hits blockbuster status

August 5, 2026 | seekingalpha.com

Elanco Animal Health Incorporated 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, ELAN, CORT, and AXSM Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$25.29 -1.14 (-4.31%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$25.34 +0.05 (+0.20%)

As of 08/7/2026 07:34 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Axsome Therapeutics NASDAQ:AXSM

$212.74 +2.61 (+1.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$211.84 -0.90 (-0.42%)

As of 08/7/2026 07:59 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$110.77 +2.82 (+2.61%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$111.03 +0.26 (+0.23%)

As of 08/7/2026 07:45 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health NYSE:ELAN

$22.06 -2.14 (-8.85%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$22.33 +0.27 (+1.23%)

As of 08/7/2026 07:54 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARQT, ELAN, CORT, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARQT, ELAN, CORT, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARQT, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, ELAN, CORT, and AXSM Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARQT, ELAN, CORT, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARQT, ELAN, CORT, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARQT, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, ELAN, CORT, and AXSM Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools